Amgen agrees to $200M settlement with J&J unit

Amgen will pay Johnson & Johnson's Ortho Biotech Products $200 million to end litigation involving three drugs that boost blood cells. Amgen was accused of violating antitrust laws when it offered discounts and incentives to oncology clinics for Aranesp, Neupogen and Neulasta. The company denies any wrongdoing.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI